Depression, Major Depressive Disorder
Conditions
Keywords
depression, older adult, buprenorphine, Effexor XR, treatment resistant, venlafaxine, Saint Louis, late life, major depression
Brief summary
The investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patients with difficult to treat depression. This research study is testing whether combining two medications will be effective in treating depression when initial treatment with just one antidepressant does not relieve the depressive symptoms; this is what is called difficult to treat depression or treatment resistant depression. The two medications the investigators are using are: an anti-depressant medication called venlafaxine extended release (venlafaxine XR), which is the generic form of Effexor, and buprenorphine. Buprenorphine is a medication that is FDA approved for the treatment of opioid dependence. The investigators are testing whether adding buprenorphine to venlafaxine XR enhances treatment response.
Detailed description
We will consent approximately 100 participants, aged 50 and older, of both sexes and all races. Participation may last up to 32 weeks. We will utilize a clinical trial that has 3 Phases. In Phase 1 we will treat participants with an approximate 12 week course of open-label venlafaxine XR. This is the same lead-in treatment as in our ongoing IRL Grey (Incomplete Response in Late Life Depression: Getting to Remission) multi-site R01 for late-life treatment resistant depression (LL-TRD), and we have found it to be highly successful. Participants who find relief from their depressive symptoms on venlafaxine XR alone will exit the study. Participants meeting criteria for an incomplete response (those still feeling depressed or withdrawn), will be randomly assigned to receive either low-dose buprenorphine or placebo augmentation of venlafaxine xr for 8 weeks (Phase 2), with the goal of achieving remission. Subjects will start at 0.2mg and titrate up as needed to 1.2mg. Subjects may undergo up to 2 MRI scans at the beginning and end of Phase 2 as well as cognitive testing at the same time points. At the conclusion of Phase 2, the blind will be broken for all participants. The participants who were on placebo will be able to begin taking buprenorphine immediately for Phase 3 (approximately 8 weeks). The participants who were already on buprenorphine in Phase 2 can continue to take it during Phase 3. Buprenorphine (BPN) will be tapered upon exiting the study, under the guidance of the P.I. The Phase 3 variations will allow all participants a chance to experience the benefits of buprenorphine (BPN). Efficacy and tolerability data will provide a clinically informative estimate of benefits and risks of buprenorphine augmentation for late-life treatment resistant depression (LL-TRD). We will randomize approximately 20 subjects into Phase 2. Additionally, we will collect buprenorphine (BPN) plasma levels on all those randomized to explore a dose-effect relationship on treatment response. A small pilot study (ages 21 and up) of up to 15 healthy control subjects will be studied over an approximate 2 week period in order to ensure all of our procedures are working and to determine that there are clinical effects from buprenorphine. Control subjects will undergo a baseline PET/MRI before taking buprenorphine. At least 24 hours after the imaging, control subjects will receive a small dose of BPN starting at 0.2 mg/day and will titrate up as tolerated to 1.2 mg/day for the first week. Each subject will remain at approximately 1.2 mg/day for the duration of the study. At the end of the study, subjects will undergo a second PET/MRI.
Interventions
DRUGvenlafaxine XR
slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
DRUGbuprenorphine
randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd
DRUGPlacebo
patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
Sponsors
Reckitt Benckiser LLC
Washington University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
for Main Study: 1. Age \> or = to 50 years. 2. Major depressive disorder (MDD), single or recurrent, as diagnosed by the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (SCID-IV). 3. Montgomery Asberg Depression Rating Scale (MADRS) \>/= to 15. 4. Has or agrees to establish a clinical relationship with primary care physician (PCP). 5. Availability of an informant (e.g., emergency contact).
Exclusion criteria
1. Inability to provide informed consent. 2. Depressive symptoms not severe enough (i.e., MADRS \< 15) at the baseline assessments 3. Dementia, as defined by Mini Mental State Exam (3MS) \< 84 and clinical evidence of dementia (e.g., memory impairment, executive dysfunction, agnosia, apraxia, aphasia, with functional impairment). 4. Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms, as diagnosed by the SCID. 5. Abuse of or dependence on alcohol or other substances within the past 3 months as determined by SCID, and confirmed by study physician interview. 6. Drinking 15 or more drinks per week or consuming 5 or more drinks on any one occasion in the past week. 7. High risk for suicide (e.g., active SI and/or current/recent intent or plan) and unable to be managed safely in the clinical trial (e.g., unwilling to be hospitalized). Urgent psychiatric referral will be made in these cases. 8. Contraindication to venlafaxine XR or BPN as determined by PCP and study physician including history of intolerance of either venlafaxine XR or BPN in the study target dosage range (venlafaxine XR at up to 300 mg/day; BPN at up to 2 mg/day). 9. Inability to communicate in English (i.e., interview cannot be conducted without an interpreter; subject largely unable to understand questions and cannot respond in English). 10. Non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview). 11. Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management. This will be determined based on information from the patient's personal physician and study physician's clinical judgment. Referral to the patient's personal physician or to a general practitioner will be made in these cases. 12. Subjects taking psychotropic medications that cannot be safely tapered and discontinued prior to study initiation. The following exceptions are allowed if they have been taken at a stable dose for at least 4 weeks prior to study entry and there is not a plan to change the dose during the next 28 weeks: benzodiazepines up to 2 mg/d lorazepam equivalent; other sedative-hypnotics (e.g., zolpidem, zaleplon, eszopiclone); gabapentin if prescribed for non-psychiatric indication (e.g., neuropathy). 13. History of opioid abuse or dependence. 14. Severe pain, defined as \> 7 on 0-10 numeric rating scale for pain. 15. Concomitant use of strong or moderate CYP3A4 inhibitor (indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, telithromycin, aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil, diltiazem). 16. Refusal to stop all opioids (to avoid precipitating opioid withdrawal). 17. Hepatic impairment 18. Estimated Glomerular Filtration Rate (GFR) \< 20 ml/min. 19. Inability/refusal to identify a person as an emergency contact. 20. Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Montgomery-Asberg Depression Rating Scale (MADRS) | Baseline and 8 weeks | Measure of depression severity, range of 0-60, with higher scores indicating more severe depression. We calculated the mean change in depression for both groups using baseline MADRS and week 8 MADRS scores. |
| Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) | Week 1 and week 8 | Three item side effect scale used to assess frequency and intensity of side effects (range 0-6 for each item). We calculated the total score of all three items (range 0-18) with lower numbers indicating less frequency. We calculated the mean score at baseline and week 8 (final timepoint). |
| Antidepressant Side Effect Checklist (ASEC) | Baseline and 8 weeks | Measure of side effects, consisting of 21 items, ranging from 0-3 (0 indicates no side effect, 3 indicates severe side effect). We calculated the total final score for the 21 items (total range is 0-63). A higher total number represents a greater severity in reported side effects. We calculated the mean change in side effects for both groups using baseline and 8 week data. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Suicide Ideation Scale (SIS) | Baseline and 8 weeks | A 19 item scale used to measure the presence or absence of suicidal ideations and the degree of severity of suicidal ideas. For this study, we computed the total score for all 19 items (total range 0-90). Higher scores represent a worse outcome. We also calculated the mean change in suicidal ideation for both groups using baseline and week 8 (final timepoint). |
| Brief Symptom Inventory-Anxiety Subscale (BSI) | Baseline and 8 weeks | Measure of anxiety. Six anxiety symptoms are rated based on how distressed the subject is for each symptom. The range for each symptom is 0-4, with 4 representing extreme distress. We computed the mean of the final BSI score (range 0-24), with a lower number indicating a better outcome. We also calculated the mean change in anxiety for both groups using baseline and Phase 2 week 8 (final time point) data. |
| Numeric Scale of Pain (NRS-P) | Baseline and 8 weeks | Measure used to assess pain, ranging from 0-10, with 10 being the worst possible pain. We calculated the mean change in pain for both groups using baseline and week 8 (last time point). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Buprenorphine Drug: buprenorphine Low-dose buprenorphine (range 0.2mg/day-2.0mg/day) | 12 |
| Placebo Drug: matched placebo | 6 |
| Total | 18 |
Baseline characteristics
| Characteristic | Placebo | Total | Buprenorphine |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 10 Participants | 8 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants | 8 Participants | 4 Participants |
| Age, Continuous | 60.8 years STANDARD_DEVIATION 8.8 | 64 years STANDARD_DEVIATION 9.3 | 65.6 years STANDARD_DEVIATION 9.5 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 6 Participants | 17 Participants | 11 Participants |
| Region of Enrollment United States | 6 participants | 18 participants | 12 participants |
| Sex: Female, Male Female | 4 Participants | 14 Participants | 10 Participants |
| Sex: Female, Male Male | 2 Participants | 4 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 12 | 0 / 6 |
| other Total, other adverse events | 12 / 12 | 4 / 6 |
| serious Total, serious adverse events | 1 / 12 | 1 / 6 |
Outcome results
Primary
Antidepressant Side Effect Checklist (ASEC)
Measure of side effects, consisting of 21 items, ranging from 0-3 (0 indicates no side effect, 3 indicates severe side effect). We calculated the total final score for the 21 items (total range is 0-63). A higher total number represents a greater severity in reported side effects. We calculated the mean change in side effects for both groups using baseline and 8 week data.
Time frame: Baseline and 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Buprenorphine | Antidepressant Side Effect Checklist (ASEC) | Change in ASEC | 1 units on a scale | Standard Deviation 7 |
| Buprenorphine | Antidepressant Side Effect Checklist (ASEC) | Final ASEC score | 11.4 units on a scale | Standard Deviation 7.6 |
| Placebo | Antidepressant Side Effect Checklist (ASEC) | Change in ASEC | 1.8 units on a scale | Standard Deviation 5.5 |
| Placebo | Antidepressant Side Effect Checklist (ASEC) | Final ASEC score | 8.5 units on a scale | Standard Deviation 7.8 |
Primary
Frequency, Intensity, and Burden of Side Effects Rating (FIBSER)
Three item side effect scale used to assess frequency and intensity of side effects (range 0-6 for each item). We calculated the total score of all three items (range 0-18) with lower numbers indicating less frequency. We calculated the mean score at baseline and week 8 (final timepoint).
Time frame: Week 1 and week 8
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Buprenorphine | Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) | Mean baseline score | 5.6 score on a scale | Standard Deviation 3.9 |
| Buprenorphine | Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) | Final FIBSER Score | 3.8 score on a scale | Standard Deviation 4 |
| Placebo | Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) | Mean baseline score | 1.3 score on a scale | Standard Deviation 3.2 |
| Placebo | Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) | Final FIBSER Score | .5 score on a scale | Standard Deviation 1.2 |
Primary
Montgomery-Asberg Depression Rating Scale (MADRS)
Measure of depression severity, range of 0-60, with higher scores indicating more severe depression. We calculated the mean change in depression for both groups using baseline MADRS and week 8 MADRS scores.
Time frame: Baseline and 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Buprenorphine | Montgomery-Asberg Depression Rating Scale (MADRS) | Change in MADRS | -1 units on a scale | Standard Deviation 6.8 |
| Buprenorphine | Montgomery-Asberg Depression Rating Scale (MADRS) | Final MADRS Score | 21.3 units on a scale | Standard Deviation 6.7 |
| Placebo | Montgomery-Asberg Depression Rating Scale (MADRS) | Change in MADRS | -5.3 units on a scale | Standard Deviation 8.8 |
| Placebo | Montgomery-Asberg Depression Rating Scale (MADRS) | Final MADRS Score | 15.3 units on a scale | Standard Deviation 11.5 |
Secondary
Brief Symptom Inventory-Anxiety Subscale (BSI)
Measure of anxiety. Six anxiety symptoms are rated based on how distressed the subject is for each symptom. The range for each symptom is 0-4, with 4 representing extreme distress. We computed the mean of the final BSI score (range 0-24), with a lower number indicating a better outcome. We also calculated the mean change in anxiety for both groups using baseline and Phase 2 week 8 (final time point) data.
Time frame: Baseline and 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Buprenorphine | Brief Symptom Inventory-Anxiety Subscale (BSI) | Change in BSI | .7 units on a scale | Standard Deviation 2.8 |
| Buprenorphine | Brief Symptom Inventory-Anxiety Subscale (BSI) | Final BSI score | 3 units on a scale | Standard Deviation 3.7 |
| Placebo | Brief Symptom Inventory-Anxiety Subscale (BSI) | Change in BSI | 0 units on a scale | Standard Deviation 1.3 |
| Placebo | Brief Symptom Inventory-Anxiety Subscale (BSI) | Final BSI score | 2.7 units on a scale | Standard Deviation 3.8 |
Secondary
Numeric Scale of Pain (NRS-P)
Measure used to assess pain, ranging from 0-10, with 10 being the worst possible pain. We calculated the mean change in pain for both groups using baseline and week 8 (last time point).
Time frame: Baseline and 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Buprenorphine | Numeric Scale of Pain (NRS-P) | Change in NRS-P | -1.1 units on a scale | Standard Deviation 2.4 |
| Buprenorphine | Numeric Scale of Pain (NRS-P) | Final NRS-P score | 2.9 units on a scale | Standard Deviation 2 |
| Placebo | Numeric Scale of Pain (NRS-P) | Change in NRS-P | -1.3 units on a scale | Standard Deviation 2 |
| Placebo | Numeric Scale of Pain (NRS-P) | Final NRS-P score | 2.8 units on a scale | Standard Deviation 3.2 |
Secondary
Suicide Ideation Scale (SIS)
A 19 item scale used to measure the presence or absence of suicidal ideations and the degree of severity of suicidal ideas. For this study, we computed the total score for all 19 items (total range 0-90). Higher scores represent a worse outcome. We also calculated the mean change in suicidal ideation for both groups using baseline and week 8 (final timepoint).
Time frame: Baseline and 8 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Buprenorphine | Suicide Ideation Scale (SIS) | Change in SIS | -.2 units on a scale | Standard Deviation 4.7 |
| Buprenorphine | Suicide Ideation Scale (SIS) | Final SIS score | 1.1 units on a scale | Standard Deviation 3.5 |
| Placebo | Suicide Ideation Scale (SIS) | Change in SIS | -1 units on a scale | Standard Deviation 3 |
| Placebo | Suicide Ideation Scale (SIS) | Final SIS score | 4.7 units on a scale | Standard Deviation 11.4 |